1Lyman SD, James L, Vanden BT, et al. Molecular cloning of a ligand for the flt3/flk2 tyrosine kinase receptor:a proliferative factor for primitive hematopoietic cells[J]. Cell, 1993,75(6): 1157-1167.
2Lyman SD,Stocking K,Davison B,et al. Structural analysis of human and murine Flt3 ligand genomic loci[J]. Oncogene, 1995,11 (6) : 1165-1172.
3McClanahan T, Culpepper J, Campbell D, et al. Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand[J]. Blood, 1996,88(9) :3371-3382.
4RosnetO,Marchetto S,de LapeyriereO,et al. Murine Flt3,a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family [J]. Oncogene, 1991,6 (9): 1641- 1650.
5Chaudhry UI,Katz SC, Kingham TP. In vivo over expression of Flt3 ligand expands and activates murine spleen natural killer dendritic cells[J]. FASEB, 2006,20(7) : 982-984.
6Sang H, Pisarev VM, Chavez J, et al. Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses[J]. Cancer Gene Ther, 2005,12(4) :427-437.
7Shimao K, Takayama T, Enomoto K, et al. Cancer gene therapy using in vivo electroporation of Flt3-ligand[J]. lnt J Oncol,2005,27(2) :457-463.
8Yoon WS, Choi WC, Sin JI, et al. Antitumor therapeutie effects of salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse [J]. Biotechnol Lett, 2007,29 (4) : 511-516.
9Ali S, Zirger JM, Curtin JF, et al. Inflammatory and antiglioma effects of an adenovirus expressing human soluble Fms-like tyrosine kinase 3 ligand (hsFlt3L):treatment with hsFlt3L inhibits intracranial glioma progression [J ]. Mol Ther,2004,10(6) : 1071-1084.
10Ali S, King GD, Curtin JF, et al. Combined immunostimulation and conditional eytotoxic gene therapy provide long-term survival in a large glioma model[J]. Cancer Res,2005,65(16) :7194-7204.
